TLIK — Arzneiwerk VIDA AG Share Price
Last trade - 00:00- €5.67m
- €17.19m
- €59.28m
- 35
- 65
- 20
- 31
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.09 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -3.51% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 4.16 | 2.82 | 2.36 | 73.37 | 59.28 | n/a | n/a | 62.34% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | -85.8 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Arzneiwerk VIDA AG, formerly Teles AG, is a Germany-based financial holding company. The Company is active in the pharmaceutical segment, where it focuses on the growth area of Specialty Pharma in Germany and Europe. Specialty Pharma usually includes high-priced drugs for chronic, complex, or rare diseases. It focuses on six indication areas: oncology, neurology, autoimmune diseases, ophthalmology, hemophilia, and infectious diseases. The Pharma segment combines pharmaceutical supply with a focus on digitalization and process optimization along the pharmaceutical value chains and the management of large data volumes in the pharmaceutical industry.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- November 6th, 1996
- Public Since
- November 14th, 2007
- No. of Employees
- 52
- Sector
- Telecommunications Services
- Industry
- Telecoms
- Exchange
- XETRA
- Shares in Issue
- 6,233,418
- Address
- Ordensmeisterstr. 15-16, BERLIN, 12099
- Web
- https://www.teles.com/
- Phone
- +49 30399280900
- Auditors
- MSW GmbH
Upcoming Events for TLIK
Similar to TLIK
FAQ
As of Today at 19:20 UTC, shares in Arzneiwerk VIDA AG are trading at €0.91. This share price information is delayed by 15 minutes.
Shares in Arzneiwerk VIDA AG last closed at €0.91 and the price had moved by -15.74% over the past 365 days. In terms of relative price strength the Arzneiwerk VIDA AG share price has underperformed the FTSE Global All Cap Index by -26.72% over the past year.
There is no consensus recommendation for this security.
Find out moreArzneiwerk VIDA AG does not currently pay a dividend.
Arzneiwerk VIDA AG does not currently pay a dividend.
Arzneiwerk VIDA AG does not currently pay a dividend.
To buy shares in Arzneiwerk VIDA AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €0.91, shares in Arzneiwerk VIDA AG had a market capitalisation of €5.67m.
Here are the trading details for Arzneiwerk VIDA AG:
- Country of listing: Germany
- Exchange: GER
- Ticker Symbol: TLIK
Based on an overall assessment of its quality, value and momentum Arzneiwerk VIDA AG is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arzneiwerk VIDA AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -27.55%.
As of the last closing price of €0.91, shares in Arzneiwerk VIDA AG were trading -16.84% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Arzneiwerk VIDA AG PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.91.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Arzneiwerk VIDA AG's management team is headed by:
- Joachim Schwarzer - CSU
- Oliver Olbrich - CMG
- Markus Schmieta - VSU
- Hartmut Brandt - SUB